Incyte (INCY) Convertible Debt (2010 - 2020)

Incyte's (INCY) quarterly Convertible Debt came in at $20.7 million in Q3 2020, down 45.83% on a QoQ basis from $38.3 million in Q2 2020.

Incyte (INCY) Convertible Debt (2010 - 2020) Analysis & Trends

Incyte (INCY) has 11 years of Convertible Debt data on file, last reported at $20.7 million in Q3 2020.

Quarterly Convertible Debt changed N/A year-over-year to $20.7 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $20.7 million (changed N/A YoY) and the FY2019 annual result came in at $32.5 million, up 86.48% from the prior year.
Convertible Debt declined to $20.7 million in Q3 2020, from $38.3 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $651.5 million in Q4 2016 to a low of $16.6 million in Q4 2017.
A 5-year average of $160.4 million and a median of $23.6 million in 2017 frame the typical range for Convertible Debt.
Annual changes were most pronounced in 2017 — Convertible Debt sank 97.45% — and 2020, when it jumped 114.41%.
Tracing INCY's Convertible Debt over 5 years: stood at $651.5 million in 2016, then slumped by 97.45% to $16.6 million in 2017, then rose by 4.97% to $17.4 million in 2018, then soared by 86.48% to $32.5 million in 2019, then tumbled by 36.18% to $20.7 million in 2020.
The last three Convertible Debt figures came in at $20.7 million (Q3 2020), $38.3 million (Q2 2020), and $27.7 million (Q1 2020), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Incyte	24.15 Bn	19.61 Bn	1.57 Bn

Download Data